Introduction
T-cell large granular lymphocyte leukemia (LGLL) is a rare clonal disorder in which a monoclonal T-cell population accumulates in the blood, bone marrow, spleen, and liver. 1 The main clinical manifestations are cytopenia (mostly neutropenia), splenomegaly, and recurrent infections. 2 T-cell LGLL is associated with rheumatoid arthritis (RA) in up to one-third of cases. 3 No large prospective trials have been conducted in LGLL. 4 Lowdose methotrexate and short-term prednisone are the main first-line drugs. 5, 6 The overall 3-month response rate is only 55%, and most responders relapse after 1 year of treatment. 7 Refractory disease may respond to cyclosporine, cyclophosphamide, 4 or alemtuzumab. 8, 9 Complete remissions are rare. Rituximab is a monoclonal anti-CD20 antibody approved for B-cell non-Hodgkin lymphoma 10 and RA. 11 Rituximab induces complete depletion of circulating B cells with no direct effects on T cells. No data have been published on rituximab therapy in patients with both RA and LGLL. Here, we describe 2 cases. This study is a retrospective review of clinical cases. No ethics committee consultation was required, but informed consent was obtained from both patients according to the Declaration of Helsinki.
Study design Case 1
A woman born in 1932 was diagnosed in 1998 with erosive rheumatoid factor-positive RA. Subsequent tests were positive for anti-citrullinated protein antibody. Within a few months, severe neutropenia developed (Figure 1) , and investigations showed a monotypic T-cell receptor (TCR)ab
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1 T-cell LGL population in the blood and bone marrow.
The absolute blood LGL count was 2. , and low-dose methotrexate and prednisone were started. Three months later, neither the joint disease nor the leukemia was improved. Two 1000-mg rituximab infusions provided a rapid remission of the joint disease accompanied with immediate neutrophil count normalization despite persistence of the monoclonal T-cell population. Six months later, a second rituximab course was given for exacerbation of the joint symptoms. In January 2013, the RA was still in remission despite prednisone discontinuation, neutrophil counts remained normal, and the leukemic cell count was substantially decreased. DAS28, RA disease activity score evaluating 28 joints; MTX, methotrexate.
Hematological investigations disclosed a monotypic TCR-ab
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1 LGL population representing 50% of blood and bone marrow lymphocytes (absolute blood LGL count, 2.1 G/L). TCR-Vb flow cytometry showed a defective repertoire, and clonality was demonstrated by TCR-gene rearrangement analysis. He had no splenomegaly or lymphadenopathy. T-cell LGLL was diagnosed, but the only treatment was a G-CSF injection in September 2011. In November 2011, rheumatoid factor-and anti-citrullinated protein antibody-positive RA was diagnosed. Methotrexate and prednisone were started, but 3 months later the joint symptoms had worsened despite a prednisone dosage increase to 20 mg/d. The neutrophil blood count was 0.49 G/L, and the lymphocyte count was 6.6 G/L. A tumor necrosis factor a antagonist was not deemed appropriate given the clonal disease. Two 1000-mg rituximab infusions were given in February 2012 and rapidly induced a remission of the RA. The neutrophil count returned to normal after the first rituximab infusion and subsequently remained within the normal range. In July 2012, an increase in RA activity prompted a second rituximab course. The total lymphocyte count was normal (2.7 G/L), but the phenotype showed 40% monotypic CD3 
Results and discussion
To our knowledge, our 2 patients are the first reported cases of successful rituximab therapy in RA-associated T-cell LGLL. The long-term follow-up in the first patient indicates that rituximab can produce a sustained improvement and even a complete remission of LGLL. Rituximab was well tolerated in both patients. Two pathogenic theories have been proposed for T-cell LGLL. The initiating event leading to the monoclonal T-cell proliferation may be an acquired intrinsic molecular defect, such as a mutation. A recent study identified a somatic mutation in the signal transducer and activator of the transcription 3 gene in 31 (40%) of 77 LGLL patients, with a higher proportion (73%) in patients with RA.
12 Such a mutation may cause the development of a monoclonal T-cell population.
Alternatively, the T-cell expansion may be driven by a combination of persistent antigenic stimulation and immunogenetic factors.
LGLL cells exhibit the phenotype and genotype of cells subjected to chronic antigen activation, which may initiate clonal transformation. Serial measurements in 71 patients with T-cell LGLL showed that the dominant clonal population contracted or even disappeared over time in 26 (37%) patients, with or without a link to treatment, and was replaced by another clonal population expressing a different Vb region. 13 These findings suggest that, in some cases, development of the clonal population may be a reactive process unrelated to an intrinsic molecular defect. In RA, the effects of rituximab on the immune system may consist not only in transient B-cell depletion, but also in changes in the microenvironment and cytokine balance capable of impairing LGL clone survival without directly affecting the leukemic LGLs. This mechanism would explain the gradual shrinkage of the monoclonal population in our patients, until complete disappearance after several months in our first patient. Late-onset neutropenia is a rare and usually transient complication of rituximab therapy in patients with malignant and rheumatic disorders. 14, 15 In some of these patients, an increase in
LGLs in the peripheral blood and bone marrow was described, with no monoclonality by TCR gene analysis. 16, 17 As illustrated by our first patient, T-cell LGLL is frequently associated with concomitant low-grade B-cell dyscrasias, such as monoclonal gammopathy of unknown significance or chronic lymphocytic leukemia, suggesting that a common antigen may drive both T-and B-cell proliferation. 18 In conclusion, rituximab therapy may be safe and effective in LGLL-related neutropenia in RA patients and may produce a longterm complete remission of LGLL. The paradoxical efficacy of this specific anti-B-cell therapy on a T-cell monoclonal disease suggests that, in some cases, T-cell LGLL may be a reactive manifestation of chronic autoantigen stimulation rather than a true malignancy. Studies are warranted to assess our preliminary findings.
